查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2039926

頭頸部鱗狀細胞癌：新型療法、未滿足的需求和TPP洞察報告，2026年

Head and Neck Squamous Cell Carcinoma - Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026
出版日期: | 出版商: Thelansis Knowledge Partners | 英文 53 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

市場概覽

  • 法國頭頸部鱗狀細胞癌（HNSCC）市場預計將從2025年的1.05億美元成長到2035年的3.35億美元，這反映了在免疫療法日益普及的推動下，該市場實現了強勁的兩位數成長。
  • 市場擴張受以下因素支撐：
  • 免疫查核點抑制劑（PD-1抑制劑）的廣泛應用
  • 晚期疾病中聯合治療的廣泛應用
  • 雖然患者數量相對穩定成長，但市場規模的成長主要受癌症藥物高昂成本和治療時間延長的影響。
  • 未來的成長取決於免疫腫瘤學、標靶治療和目的是提高存活率的個人化治療策略的進步。

頭頸部鱗狀細胞癌（HNSCC）的新型治療方法和 TPP 見解

Thelansis 發布的《頭頸部鱗狀細胞癌：新型療法、未滿足的需求和TPP洞察報告，2026年》全面分析了該適應症的關鍵新興治療方法和主要藥物發現機會，包括新興的競爭格局、未滿足的需求、目標產品概況（TPP）、試驗設計和關鍵意見領袖（KOL）的見解。

頭頸部鱗狀細胞癌（HNSCC）概述

頭頸部鱗狀細胞癌（HNSCC）是一組生物學異質性強、侵襲性高的惡性腫瘤，發生於口腔、咽喉和喉部的黏膜上皮。它是全球最常見的癌症之一，其發展發展主要與兩個途徑有關：長期接觸菸草和酒精，以及感染高風險型人類乳突病毒（HPV）。

HPV陽性頭頸部鱗狀細胞癌（HNSCC），尤其是口咽癌，因其預後良好且治療反應率高於HPV陰性病例，而作為一種獨特的臨床亞型備受關注，儘管其常伴有晚期淋巴結轉移。大多數患者確診時已處於局部晚期，需要多學科綜合治療以盡可能保留功能，包括手術、放射線治療以及含鉑類藥物合併放射線治療。然而，復發率仍然很高，相當一部分患者會發展為復發/轉移性疾病（R/M）。

隨著PD-1標靶免疫查核點抑制劑的引進，復發/轉移性頭頸部鱗狀細胞癌（R/M HNSCC）的治療模式發生了顯著變化。這些藥物構成了治療的基礎，既可作為單一藥物治療，也可與化療聯合治療。儘管取得了這些進展，但整體預後仍然較差，凸顯了開發更有效、更持久的治療策略的必要性。

主要亮點

  • 在美國，預期盛行率（經存活已調整的病例）將從2025年的404,100 例增加到2035年的432,300 例，反映出穩定成長（年複合成長率為 0.7%）。
  • 高復發率和進展為轉移性疾病仍然是主要的臨床挑戰，晚期的長期存活率有限。
  • 免疫療法和基於生物標記的治療方法的日益普及，大幅改變治療格局，尤其是對於復發和轉移性病例而言。

基於對醫生和關鍵意見領袖（KOL）的調查得出的結論：

  • 透過對關鍵意見領袖（KOL）的訪談，獲得了更多見解，進一步完善了調查結果。
  • 調查問卷將根據客戶的要求進行客製化。

交付成果格式：

  • PowerPoint簡報
  • MS Excel

主要問題

  • 詳細的競爭格局趨勢
  • 管道分析
  • 符合新興治療方法的患者
  • 主要企業
  • 主要作用機制
  • 發布日期等的預測
  • 臨床試驗趨勢分析
  • 目標患者群
  • 試驗終點
  • 測試設計
  • 受試者招募標準等
  • 未滿足的需求和機會
  • 目前主要治療方法的有效性
  • 未滿足需求的關鍵領域
  • 估算主要未滿足需求的市場規模
  • 目標產品概況
  • 屬性和級別
  • 醫生開立的處方
  • 預期患者佔有率
  • 關鍵KOL洞察對領先新興治療方法的見解
  • 意識
  • 預期用途/處理線
  • 對主要未滿足需求的滿意度
  • KOL評論

目標國家

  • G8
    • 美國
    • EU5
      • 法國
      • 德國
      • 義大利
      • 西班牙
      • 英國
    • 日本
    • 中國

大公司

  • Fulgent Pharma LLC.
  • CSPC Megalith Biopharmaceutical Co., Ltd.
  • Gilead Sciences
  • Merck Sharp &Dohme LLC
  • Sichuan Baili Pharmaceutical Co., Ltd.
  • Transgene
  • Regeneron Pharmaceuticals
  • Inhibrx Biosciences, Inc
  • AstraZeneca
  • Coherus Oncology, Inc.
  • Ipsen
  • Radiopharm Theranostics, Ltd
  • KaliVir Immunotherapeutics
  • IDEAYA Biosciences
  • ImmunityBio, Inc.
  • Rondo Therapeutics
  • AbbVie
  • Sutro Biopharma, Inc.
  • SystImmune Inc.
  • Zumutor Biologics Inc.
  • Arcus Biosciences, Inc.
  • Normunity AccelCo, Inc.

目錄

第1章 主要調查結果及分析師說明

  • 主要趨勢：市場概況、SWOT分析、商業性利益與風險等。

第2章 競爭情勢

  • 目前的治療方法
  • 重點
  • 診斷和治療過程/演算法
  • 主要治療方法概述及KOL洞察
  • 新興治療方法
  • 重點
  • 診斷和治療過程/演算法
  • 領先的新興治療方法 - 概述和KOL洞察

第3章 產品屬性分析

  • 重點
  • 科學屬性
  • 商業屬性
  • 產品定位

第4章 初步調查

  • 目前治療狀態
  • 主要治療方法與目標患者族群的比較
  • 主要特點和優勢
  • 未來治療環境
  • 當前挑戰
  • 未滿足的需求
  • 新興治療方法
  • 主要治療方法與目標患者族群的比較
  • 主要特點和優勢
  • 未來治療前景
  • 未滿足的需求和關鍵意見領袖的期望

第5章 未滿足的需求和TPP分析

  • 主要未滿足需求和新興治療方法的未來成就
  • TPP分析與KOL預期

第6章 法規與償付環境

第7章 附錄

簡介目錄

Head and Neck Squamous Cell Carcinoma (HNSCC) Emerging Therapy and TPP Insights

Thelansis's "Head and Neck Squamous Cell Carcinoma (HNSCC) Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026" provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Head and Neck Squamous Cell Carcinoma (HNSCC) Overview

Head and Neck Squamous Cell Carcinoma (HNSCC) is a biologically heterogeneous and highly aggressive group of malignancies arising from the mucosal epithelium of the oral cavity, pharynx, and larynx. It represents one of the most prevalent cancers globally and is driven by two primary etiological pathways: chronic exposure to tobacco and alcohol, and infection with high-risk human papillomavirus (HPV).

HPV-positive HNSCC, particularly in the oropharynx, has emerged as a distinct clinical subtype with improved prognosis and greater responsiveness to treatment compared to HPV-negative disease, despite often presenting with advanced nodal involvement. Most patients are diagnosed at a locally advanced stage, requiring multidisciplinary, function-preserving treatment approaches, including surgery, radiation therapy, and platinum-based chemoradiation. However, recurrence rates remain high, with a significant proportion progressing to recurrent or metastatic (R/M) disease.

The treatment paradigm for R/M HNSCC has evolved significantly with the introduction of immune checkpoint inhibitors targeting PD-1, which have become a cornerstone of therapy, either as monotherapy or in combination with chemotherapy. Despite these advances, overall prognosis remains poor, highlighting the need for more effective and durable treatment strategies.

Key Highlights

  • In the US, prevalence (survival-adjusted cases) is projected to increase from 404.1K in 2025 to 432.3K by 2035, reflecting steady growth (0.7% CAGR).
  • High rates of recurrence and progression to metastatic disease remain a major clinical challenge, with limited long-term survival in advanced stages.
  • Increasing adoption of immunotherapy and biomarker-driven treatment approaches is reshaping the therapeutic landscape, particularly in recurrent/metastatic settings.

Market Overview

  • The France HNSCC market is projected to grow from $105M in 2025 to $335M by 2035, reflecting strong double-digit growth driven by expanding use of immunotherapies.
  • Market expansion is supported by:
  • Increased uptake of immune checkpoint inhibitors (PD-1 inhibitors)
  • Broader use of combination regimens in advanced disease
  • Despite relatively stable patient growth, market value is driven by high-cost oncology therapies and extended treatment duration.
  • Future growth will depend on advancements in immuno-oncology, targeted therapies, and personalized treatment strategies to improve survival outcomes.

Insights driven by surveys* with physician / key opinion leaders:

  • Survey findings are corroborated and enriched by insights from interviews with leading KOLs
  • Survey is customized based on client requirements

Deliverables format:

  • PowerPoint presentation
  • MS Excel

Key business questions answered:

  • Detailed emerging competitive landscape
  • Pipeline analysis
  • Target patients for emerging therapies
  • Key companies
  • Key mechanism of actions
  • Launch date estimates, etc.
  • Clinical trial landscape analysis
  • Target patient segments
  • Trial endpoints
  • Trial design
  • Recruitment criteria, etc.
  • Unmet Needs and Opportunities
  • Performance of key current therapies
  • Top areas of unmet needs
  • Opportunity sizing for key unmet needs
  • Target Product Profiles
  • Attributes and levels
  • Physician likelihood of prescribing
  • Expected patient shares
  • KOL insights on key emerging therapies
  • Level of awareness
  • Expected use / line of therapy
  • Extent to fulfil key unmet needs
  • KOL quotes

Countries Covered

  • G8
    • United States
    • EU5
      • France
      • Germany
      • Italy
      • Spain
      • U.K.
    • Japan
    • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

  • Fulgent Pharma LLC.
  • CSPC Megalith Biopharmaceutical Co., Ltd.
  • Gilead Sciences
  • Merck Sharp & Dohme LLC
  • Sichuan Baili Pharmaceutical Co., Ltd.
  • Transgene
  • Regeneron Pharmaceuticals
  • Inhibrx Biosciences, Inc
  • AstraZeneca
  • Coherus Oncology, Inc.
  • Ipsen
  • Radiopharm Theranostics, Ltd
  • KaliVir Immunotherapeutics
  • IDEAYA Biosciences
  • ImmunityBio, Inc.
  • Rondo Therapeutics
  • AbbVie
  • Sutro Biopharma, Inc.
  • SystImmune Inc.
  • Zumutor Biologics Inc.
  • Arcus Biosciences, Inc.
  • Normunity AccelCo, Inc.

Table of Contents

1. Key Findings and Analyst Commentary

  • Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

  • Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies - profiles and KOL insights
  • Emerging therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key emerging therapies - profiles and KOL insights

3. Product Attribute Analysis

  • Key takeaways
  • Scientific attributes
  • Commercial attributes
  • Product positioning

4. Primary Market Research

  • Current treatment landscape
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Current challenges
  • Unmet needs
  • Emerging therapies
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

  • Top unmet needs and future attainment by emerging therapies
  • TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)